Revolution Medicines sees strong demand for pancreatic cancer drug daraxonrasib under compassionate use

Revolution Medicines reports that more than 2,000 patients have received its pancreatic cancer candidate daraxonrasib through a compassionate use program.

The company says the drug has been distributed to cancer centers nationwide, indicating strong interest despite the lack of commercial launch, and analysts have raised sales forecasts.

The FDA has allowed the compassionate use plan while the drug remains under an accelerated review pathway, and other biotech firms such as Intellia and Arrowhead are also highlighted in the roundup.